Similarly, the high EZH2 expression/IDH1 R132H-negative group predicted a significantly poorer OS outcome with a mortality risk 4.7 times higher than gliomas with low EZH2 expression/IDH1 R132H-negative group at the univariate level (p = 0.025), but this was not statistically significant at the multivariable level. The gene discussed is EZH2; the disease is central nervous system cancer.